Jardiance

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

empagliflozin

Available from:

Boehringer Ingelheim International GmbH

ATC code:

A10BK03

INN (International Name):

empagliflozin

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Diabetes Mellitus, Type 2; Heart Failure; Renal Insufficiency, Chronic

Therapeutic indications:

Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 и 5. of the annex. Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.

Product summary:

Revision: 28

Authorization status:

упълномощен

Authorization date:

2014-05-22

Patient Information leaflet

                                53
Б. ЛИСТОВКА
54
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
JARDIANCE 10 MG ФИЛМИРАНИ ТАБЛЕТКИ
JARDIANCE 25 MG ФИЛМИРАНИ ТАБЛЕТКИ
емпаглифлозин (empagliflozin)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар,
фармацевт или
медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Jardiance и за какво се
използва
2.
Какво трябва да знаете, преди да
приемeте Jardiance
3.
Как да приемате Jardiance
4.
Възможни нежелани реакции
5.
Как да съхранявате Jardiance
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА JARDIANCE И ЗА КАКВО СЕ
ИЗПОЛЗВА
КАКВО ПРЕДСТАВЛЯВА JARDIANCE
Jardiance съд
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Jardiance 10 mg филмирани таблетки
Jardiance 25 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Jardiance 10 mg филмирани таблетки
Всяка таблетка съдържа 10 mg
емпаглифлозин (empagliflozin).
_Помощни вещества с известно действие_
Всяка таблетка съдържа лактоза
монохидрат, която съответства на 154,3 mg
лактоза, безводна.
Jardiance 25 mg филмирани таблетки
Всяка таблетка съдържа 25 mg
емпаглифлозин (empagliflozin).
_Помощни вещества с известно действие_
Всяка таблетка съдържа лактоза
монохидрат, която съответства на 107,4 mg
лактоза, безводна.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка (таблетка).
Jardiance 10 mg филмирани таблетки
Кръгла, бледожълта, двойноизпъкнала
филмирана таблетка със скосени ръбове
с вдлъбнато
релефно означение „S10“ от едната
страна и логото на Boehringer Ingelheim от
другата страна
(диаметър на таблетката: 9,1 mm).
Jardiance 25 mg филмирани таблетки
Овална, бледожълта, двойноизпъкнала
филмирана таблетка с вдлъбнато
релефно означение
„S25“ от едната страна и логото на
Boehringer Ingelheim от другата страна (дължина
на
таблетката: 11,
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 29-01-2024
Public Assessment Report Public Assessment Report Spanish 17-08-2023
Patient Information leaflet Patient Information leaflet Czech 29-01-2024
Public Assessment Report Public Assessment Report Czech 17-08-2023
Patient Information leaflet Patient Information leaflet Danish 29-01-2024
Public Assessment Report Public Assessment Report Danish 17-08-2023
Patient Information leaflet Patient Information leaflet German 29-01-2024
Public Assessment Report Public Assessment Report German 17-08-2023
Patient Information leaflet Patient Information leaflet Estonian 29-01-2024
Public Assessment Report Public Assessment Report Estonian 17-08-2023
Patient Information leaflet Patient Information leaflet Greek 29-01-2024
Public Assessment Report Public Assessment Report Greek 17-08-2023
Patient Information leaflet Patient Information leaflet English 29-01-2024
Public Assessment Report Public Assessment Report English 17-08-2023
Patient Information leaflet Patient Information leaflet French 29-01-2024
Public Assessment Report Public Assessment Report French 17-08-2023
Patient Information leaflet Patient Information leaflet Italian 29-01-2024
Public Assessment Report Public Assessment Report Italian 17-08-2023
Patient Information leaflet Patient Information leaflet Latvian 29-01-2024
Public Assessment Report Public Assessment Report Latvian 17-08-2023
Patient Information leaflet Patient Information leaflet Lithuanian 29-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-01-2024
Public Assessment Report Public Assessment Report Lithuanian 17-08-2023
Patient Information leaflet Patient Information leaflet Hungarian 29-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 29-01-2024
Public Assessment Report Public Assessment Report Hungarian 17-08-2023
Patient Information leaflet Patient Information leaflet Maltese 29-01-2024
Public Assessment Report Public Assessment Report Maltese 17-08-2023
Patient Information leaflet Patient Information leaflet Dutch 29-01-2024
Public Assessment Report Public Assessment Report Dutch 17-08-2023
Patient Information leaflet Patient Information leaflet Polish 29-01-2024
Public Assessment Report Public Assessment Report Polish 17-08-2023
Patient Information leaflet Patient Information leaflet Portuguese 29-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 29-01-2024
Public Assessment Report Public Assessment Report Portuguese 17-08-2023
Patient Information leaflet Patient Information leaflet Romanian 29-01-2024
Public Assessment Report Public Assessment Report Romanian 17-08-2023
Patient Information leaflet Patient Information leaflet Slovak 29-01-2024
Public Assessment Report Public Assessment Report Slovak 17-08-2023
Patient Information leaflet Patient Information leaflet Slovenian 29-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 29-01-2024
Public Assessment Report Public Assessment Report Slovenian 17-08-2023
Patient Information leaflet Patient Information leaflet Finnish 29-01-2024
Public Assessment Report Public Assessment Report Finnish 17-08-2023
Patient Information leaflet Patient Information leaflet Swedish 29-01-2024
Public Assessment Report Public Assessment Report Swedish 17-08-2023
Patient Information leaflet Patient Information leaflet Norwegian 29-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 29-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 29-01-2024
Public Assessment Report Public Assessment Report Croatian 17-08-2023

Search alerts related to this product

View documents history